CHAPTER 109 — REFERENCES

1. Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. *N Engl J Med* 2003;349:1451–1464.
2. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. *Blood* 2008;112:4808–4817.
3. Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best *Pract Res Clin Haematol* 2009;22:295–302.
4. Brown WM, Doll R. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. *Br Med J* 1965;5474:1327–1332.
5. Curtis RE, Boice JD Jr, Stovall M, et al. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. *J Natl Cancer Inst* 1994;86:1315–1324.
6. Kato H, Schull WJ. Studies of the mortality of A-bomb survivors. 7. Mortality, 1950-1978: Part I. Cancer mortality. *Radiat Res* 1982;90:395–432.
7. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. *Science* 1960;132:1497.
8. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. *Nature* 1973;243:290–293.
9. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. *Blood* 2000;96:3343–3356.
10. de Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. *Nature* 1982;300:765–767.
11. Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, *bcr*, on chromosome 22. *Cell* 1984;36:93–99.
12. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. *Cell* 1984;37:1035–1042.
13. Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. *Science* 1990;247:1079–1082.
14. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. *Br J Haematol* 1997;96:111–116.
15. Vardiman JW, Pierre RV, Thiele J, et al. Chronic myelogenous leukaemia. In: Jaffe SE, Harris NL, Stein H, et al, eds. *World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon: IARC Press; 2001: 20–26.
16. El-Zimaity MM, Kantarjian H, Talpaz M, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. *Br J Haematol* 2004;125:187–195.
17. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. *Leuk Lymphoma* 1993;11:11–15.
18. Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. *Blood* 2012;120:761–767.
19. Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. *Blood* 2011;118:6760–6768.
20. Cortes JE, Talpaz M, Beran M, et al. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. *Cancer* 1995;75:464–470.
21. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. *J Clin Oncol* 2001;19:2915–2926.
22. Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. *Nat Genet* 2013;45:18–24.
23. Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. *N Engl J Med* 2013;368:1781–1790.
24. Wang YL, Bagg A, Pear W, et al. Chronic myelogenous leukemia: laboratory diagnosis and monitoring. *Genes Chromosomes Cancer* 2001;32:97–111.
25. DeWald GW, Wyatt WA, Juneau AL, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. *Blood* 1998;91:3357–3365.
26. Cross NC. Quantitative PCR techniques and applications. *Br J Haematol* 1995;89:693–697.
27. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. *Blood* 1984;63:789–799.
28. Druker B, Guilhot F, O'Brien S, et al. Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival. *N Engl J Med* 2006;355:2408–2417.
29. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukaemia: incidence of sustained responses in an intention-to-treat analysis. *J Clin Oncol* 2008;26:3358–3363.
30. Marin D, Marktel S, Bua M, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. *Leukemia* 2003;17:1448–1453.
31. Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure using second generation tyrosine kinase inhibitors for chronic myeloid leukemia. *Haematologica* 2010;92:224–231.
32. Sokal JE, Baccarani M, Tura S, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. *Blood* 1985;66:1352–1357.
33. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib. *J Clin Oncol* 2010;24:2381–2388.
34. Cross NC, White HE, Muller MC, et al. Standardized definitions of molecular response in chronic myeloid leukemia. *Leukemia* 2012;26:2172–2175.
35. Lin F, Chase A, Bungey J, et al. Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia. *Genes Chromosomes Cancer* 1995;13:110–114.
36. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. *Cancer Cell* 2005;7:129–141.
37. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. *Cancer Cell* 2009;16:401–412.
38. Remsing Rix LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. *Leukemia* 2009;23:477–485.
39. Manley PW, Stiefl N, Cowan-Jacob SW, et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. *Bioorg Med Chem* 2010;18:6977–6986.
40. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. *Biochim Biophys Acta* 2005;1754:3–13.
41. Marin D. Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia. *Hematology Am Soc Hematol Educ Program* 2012;2012:115–121.
42. Marin D, Ibrahim AR, Lucas CM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. *J Clin Oncol* 2012;30:232–238.
43. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. *J Clin Oncol* 2010;28:424–430.
44. Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. *Blood* 2009;113:4497–4504.
45. Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. *J Clin Oncol* 2014;32:415–423.
46. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. *N Engl J Med* 2006;354:2542–2551.
47. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. *Blood* 2011;117:1141–1145.
48. Milojkovic D, Apperley JF, Gerrard G, et al. Responses to second line tyrosine kinase inhibitors are durable: an intention to treat analysis in chronic myeloid leukemia patients. *Blood* 2012;119:1838–1843.
49. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. *Am J Hematol* 2012;86:533–539.
50. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 2010;362:2260–2270.
51. Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). *Blood* 2012;119:1123–1129.
52. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. *J Clin Oncol* 2008;26:3204–3212.
53. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. *N Engl J Med* 2006;354:2531–2541.
54. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. *Haematologica* 2010;95:232–240.

55. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. *Br J Haematol* 2008;141:745–747.
56. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. *J Clin Oncol* 2007;25:3908–3914.
57. Kim D, Goh HG, Kim SH, et al. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy. *Int J Hematol* 2011;94:361–371.
58. Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. *Cancer* 2010;116:377–386.
59. Montani D, Bergot E, Gunther S, et al. Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. *Circulation* 2012;125:2128–2137.
60. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome positive CML patients with resistance or intolerance to imatinib. *Blood* 2011;118: 4567–4576.
61. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. *J Clin Oncol* 2012;30:3486–3492.
62. Cortes JE, Maru A, Souza CAAD, et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia - BELA Trial: 24-month follow-up. *ASH Annual Meeting Abstracts* 2011;118:455.
63. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. *N Engl J Med* 2012;367:2075–2088.
64. Kantarjian HM, Kim DW, Pinilla-Ibarz J, et al. Efficacy and safety of ponatinib in patients with accelerated phase or blast phase chronic myeloid leukemia (AP-CML or BP-CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL): 12-month follow-up of the PACE Trial. *ASH Annual Meeting Abstracts* 2012;120:915.
65. Deininger MW, Cortes JE, Kantarjian HM, et al. Long-term anti-leukemic activity of ponatinib in patients with Philadelphia chromosome-positive leukemia: updated results from an ongoing phase 1 study. *ASH Annual Meeting Abstracts* 2012;120:3743.
66. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial. *ASH Annual Meeting Abstracts* 2012;120:163.
67. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 2003;348:994–1004.
68. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or sub-optimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. *Blood* 2008;112:4437–4444.
69. Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. *Blood* 2001;98: 3074–3081.
70. Ibrahim AR, Clark RE, Holyoake TL, et al. Second generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia who have failed imatinib therapy. *Haematologica* 2011;96:1779–1782.
71. Jabbour E, Kantarjian H, O'Brien S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. *Blood* 2011;118:4541–4546.
72. Quintas-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. *Blood* 2009;113:6315–6321.
73. Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). *Leukemia* 2012;26:2096–2112.
74. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. *N Engl J Med* 2003;349:1423–1432.
75. Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus Interferon-a-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. *Blood* 2006;108:1835–1840.
76. Shah N, Nicoll J, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. *Cancer Cell* 2002;2:117–223.
77. Apperley JF. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. *Lancet Oncol* 2007;8:1018–1029.
78. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. *Science* 2004;305:399–401.
79. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. *Cancer Res* 2005;65:4500–4505.
80. Redaelli S, Mologni L, Rostagno R, et al. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. *Am J Hematol* 2012;87:E125–E128.
81. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. *J Clin Invest* 2007;117:2562–2569.
82. Gratwohl A, Schwendener A, Baldomero H, et al. Changes in the use of hematopoietic stem cell transplantation: a model for diffusion of medical technology. *Haematologica* 2010;95:637–643.
83. Giralt SA, Arora M, Goldman JM, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. *Br J Haematol* 2007;137:461–467.
84. Pavlu J, Szydlo RM, Goldman JM, et al. Three decades of transplantation for chronic myeloid leukemia: what have we learned? *Blood* 2011;117:755–763.
85. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. *Blood* 2002;99:1971–1977.
86. Warlick E, Ahn KW, Pedersen TL, et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. *Blood* 2012;119:4083–4090.
87. Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. *Blood* 2005;106:2969–2976.
88. Or R, Shapira MY, Resnick I, et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. *Blood* 2003;101:441–445.
89. Olavarria E, Siddique S, Griffiths MJ, et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. *Blood* 2007;110:4614–4617.
90. Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. *Blood* 2007;109:2791–2793.
91. Klyuchnikov E, Schafhausen P, Kroger N, et al. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. *Acta Haematol* 2009;122:6–10.
92. Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. *J Clin Oncol* 2005;23:7583–7593.
93. Weisser M, Tischer J, Schnittger S, et al. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. *Haematologica* 2006;91:663–666.
94. Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. *Leukemia* 2003;17:1707–1712.
95. Wright MP, Shepherd JD, Barnett MJ, et al. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2010;16:639–646.
96. Cummins M, Cwynarski K, Marktel S, et al. Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT). *Bone Marrow Transplant* 2005;36:1065–1069.
97. Porter DL, Collins RH Jr, Shpilberg O, et al. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. *Biol Blood Marrow Transplant* 1999;5:253–261.
98. Dazzi F, Szydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. *Blood* 2000;96:2712–2716.
99. Simula MP, Marktel S, Fozza C, et al. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. *Leukemia* 2007;21: 943–948.
100. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accelerated disease in chronic myelogenous leukemia. *Cancer* 1988;61:1441–1446.
101. Calabretta B, Perrotti D. The biology of CML blast crisis. *Blood* 2004;103: 4010–4022.
102. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N Engl J Med* 2001;344:1038–1042.
103. Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. *Cancer* 2010;116:3852–3861.

104. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. *Blood* 2007;109: 3207–3213.
105. Wadhwa J, Szydlo RM, Apperley JF, et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. *Blood* 2002;99:2304–2309.
106. Rea D, Legros L, Raffoux E, et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. *Leukemia* 2006; 20:400–403.
107. Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. *Blood* 2009;113:6322–6329.
108. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. *Blood* 2007;109:58–60.
109. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. *Lancet Oncol* 2010;11:1029–1035.
110. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *N Engl J Med* 2010;362:2251–2259.
111. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. *Lancet Oncol* 2011;12:841–851.
112. Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. *Blood* 2012;120:3898–3905.